{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:01:20Z","timestamp":1784635280873,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives:\u00a0BCR::ABL1-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are clonal hematopoietic stem cell disorders characterized by chronic systemic inflammation and elevated thrombotic risk. Osteoarthritis (OA), the most prevalent joint disease globally, is common in MPNs and shares a common proinflammatory cytokine milieu with MPNs. However, whether symptomatic OA may independently impact MPN-related symptom burden and thrombotic outcomes remains unexplored. Methods: In this prospective two-center study conducted in Croatia (2021\u20132023), 107 consecutive MPN patients diagnosed by 2016 World Health Organization criteria underwent orthopedic evaluation and completed the MPN Symptom Assessment Form (MPN-SAF) at enrolment. Symptomatic OA was defined as radiographic grade \u22651 (Kellgren\u2013Lawrence) with concordant symptoms. Patients were subsequently followed for thrombotic events. Multiple linear regression and Cox proportional hazards regression were used for multivariable analyses. Results: Symptomatic OA was identified in 64 patients (59.8%). The total symptom score (TSS) was significantly higher in OA patients (p &lt; 0.001), and in multivariable analysis, OA independently predicted higher TSS (\u03b2 10.12, 95% confidence interval-CI 5.38\u201314.86, p &lt; 0.001), alongside female sex and arterial hypertension. Over a median follow-up of 44 months, 10 thrombotic events occurred. Patients with symptomatic OA had significantly worse time to thrombosis (hazard ratio-HR 3.61, 95% CI 1.02\u201312.8, p = 0.046). In multivariable Cox regression, OA remained associated with thrombosis (HR 15.55, p = 0.002), while female sex (HR 0.17, p = 0.042) and aspirin use (HR 0.15, p = 0.019) were protective. Conclusions: Symptomatic OA may be associated with higher symptom burden and, in this preliminary analysis, with higher thrombotic risk in MPNs. These findings support systematic OA evaluation in MPNs and multidisciplinary management strategies targeting this frequent and burdensome comorbidity.<\/jats:p>","DOI":"10.3390\/jcm15145663","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:54:13Z","timestamp":1784534053000},"page":"5663","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Symptomatic Osteoarthritis May Be Associated with Higher Symptom Burden and Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Prospective Two-Centre Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Hrvoje","family":"Holik","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, \u2018Dr. Josip Bencevic\u2019 General Hospital, 35000 Slavonski Brod, Croatia"},{"name":"Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-305X","authenticated-orcid":false,"given":"Ivan","family":"Krecak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, General Hospital of Sibenik-Knin County, 22000 Sibenik, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"},{"name":"University of Applied Sciences, 22000 Sibenik, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-2040","authenticated-orcid":false,"given":"Marko","family":"Lucijanic","sequence":"additional","affiliation":[{"name":"University Hospital Dubrava, 10000 Zagreb, Croatia"},{"name":"Department of Scientific Research and Translational Medicine, Clinical Hospital Dubrava, 10000 Zagreb, Croatia"},{"name":"Faculty of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Samardzic","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, \u2018Dr. Josip Bencevic\u2019 General Hospital, 35000 Slavonski Brod, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijel","family":"Pilipac","sequence":"additional","affiliation":[{"name":"Special Hospital for Orthopedics, 23210 Biograd na Moru, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Vucinic Ljubicic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u2018Dr. Josip Bencevic\u2019 General Hospital, 35000 Slavonski Brod, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozena","family":"Coha","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u2018Dr. Josip Bencevic\u2019 General Hospital, 35000 Slavonski Brod, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Kitter Pipic","sequence":"additional","affiliation":[{"name":"Department of Laboratory Diagnostics, \u2018Dr. Josip Bencevic\u2019 General Hospital, 35000 Slavonski Brod, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-3306","authenticated-orcid":false,"given":"Blazenka","family":"Miskic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u2018Dr. Josip Bencevic\u2019 General Hospital, 35000 Slavonski Brod, Croatia"},{"name":"Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Zupancic-Salek","sequence":"additional","affiliation":[{"name":"Department of Hematology and Coagulation, University Hospital Holy Spirit, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0140-6736(14)60802-3","article-title":"Osteoarthritis","volume":"386","author":"Palmer","year":"2015","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.joca.2012.11.012","article-title":"Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)","volume":"21","author":"Berenbaum","year":"2013","journal-title":"Osteoarthr. Cartil."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Holik, H., Kre\u010dak, I., Lucijani\u0107, M., Samard\u017ei\u0107, I., Pilipac, D., Ljubi\u010di\u0107, I.V., Coha, B., Pipi\u0107, A.K., Mi\u0161ki\u0107, B., and Zupan\u010di\u0107-\u0160alek, S. (2023). Hip and knee osteoarthritis in patients with chronic myeloproliferative neoplasms: A cross-sectional study. Life, 13.","DOI":"10.3390\/life13061388"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1007\/s11999-016-4732-4","article-title":"Classifications in brief: Kellgren-Lawrence classification of osteoarthritis","volume":"474","author":"Kohn","year":"2016","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3324\/haematol.2016.149559","article-title":"Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL International Working Group","volume":"102","author":"Geyer","year":"2017","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"G\u0103man, M.A., Kipkorir, V., Srichawla, B.S., Dhali, A., G\u0103man, A.M., and Diaconu, C.C. (2023). Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020388"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","article-title":"Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera","volume":"10","author":"Lussana","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2014-12-618074","article-title":"The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients","volume":"125","author":"Lau","year":"2015","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Reilly","year":"2001","journal-title":"N Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1080\/10428194.2020.1731503","article-title":"Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera","volume":"61","author":"Krecak","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00508-020-01802-x","article-title":"Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis","volume":"134","author":"Lucijanic","year":"2022","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17474086.2022.2039117","article-title":"Renal disease associated with chronic myeloproliferative neoplasms","volume":"15","author":"Lucijanic","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00277-023-05426-9","article-title":"Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives","volume":"103","author":"Krecak","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10005","DOI":"10.1016\/j.bvth.2025.100051","article-title":"Cardiovascular risk factors in myeloproliferative neoplasms: Associations with survival and thrombotic outcomes","volume":"2","author":"How","year":"2025","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1007\/s00277-023-05417-w","article-title":"Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension","volume":"102","author":"Mulas","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood-2023-179324","article-title":"Cardiovascular risk factors are common in myeloproliferative neoplasms and portend worse survival and thrombotic outcomes","volume":"142","author":"How","year":"2023","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/17474086.2015.1053456","article-title":"Bone morbidity in chronic myeloproliferative neoplasms","volume":"8","author":"Farmer","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/bloodadvances.2025017168","article-title":"Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fractures","volume":"10","author":"Lee","year":"2026","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428194.2020.1817437","article-title":"Highly increased risk of fracture in patients with myeloproliferative neoplasm","volume":"62","author":"Johansson","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/bjh.12581","article-title":"Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study","volume":"163","author":"Farmer","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Krecak, I., Lucijanic, M., and Kusec, R. (2025). Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM). J. Clin. Med., 14.","DOI":"10.3390\/jcm14051524"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.25555","article-title":"Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative","volume":"94","author":"Loscocco","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00432-016-2209-1","article-title":"Characteristics and treatment of polycythemia vera patients in clinical practice: A multicenter chart review on 1476 individuals in Germany","volume":"142","author":"Eberhardt","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5663\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:05:00Z","timestamp":1784631900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":31,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145663"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145663","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}